Growth Metrics

Acadia Pharmaceuticals (ACAD) Other Operating Expenses (2016 - 2025)

Acadia Pharmaceuticals has reported Other Operating Expenses over the past 11 years, most recently at $26.2 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $26.2 million for Q4 2025, up 121.03% from a year ago — trailing twelve months through Dec 2025 was $89.0 million (up 237.61% YoY), and the annual figure for FY2024 was $146.5 million, changed.
  • Other Operating Expenses for Q4 2025 was $26.2 million at Acadia Pharmaceuticals, up from $21.6 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for ACAD hit a ceiling of $26.2 million in Q4 2025 and a floor of -$124.7 million in Q4 2024.
  • Median Other Operating Expenses over the past 5 years was $7.1 million (2021), compared with a mean of $4.8 million.
  • Peak annual rise in Other Operating Expenses hit 1276.78% in 2024, while the deepest fall reached 797.07% in 2024.
  • Acadia Pharmaceuticals' Other Operating Expenses stood at $2.6 million in 2021, then decreased by 5.78% to $2.4 million in 2022, then surged by 641.44% to $17.9 million in 2023, then crashed by 797.07% to -$124.7 million in 2024, then skyrocketed by 121.03% to $26.2 million in 2025.
  • The last three reported values for Other Operating Expenses were $26.2 million (Q4 2025), $21.6 million (Q3 2025), and $20.7 million (Q2 2025) per Business Quant data.